EA201700019A1 - Высокочистый оритаванцин и способ его получения - Google Patents

Высокочистый оритаванцин и способ его получения

Info

Publication number
EA201700019A1
EA201700019A1 EA201700019A EA201700019A EA201700019A1 EA 201700019 A1 EA201700019 A1 EA 201700019A1 EA 201700019 A EA201700019 A EA 201700019A EA 201700019 A EA201700019 A EA 201700019A EA 201700019 A1 EA201700019 A1 EA 201700019A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
highly pure
pure orientation
oritavancin
orientation
Prior art date
Application number
EA201700019A
Other languages
English (en)
Inventor
Адел Рафай Фар
Гопал Кришна
Мин Динг
Санджей Р. Чембуркар
Карл М. Кнабле
Джеймс П. Петцель
Джули Дж. Прюйн
Дуглас М. Ример
Original Assignee
Дзе Медисинс Компани
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Медисинс Компани, Эббви Инк. filed Critical Дзе Медисинс Компани
Publication of EA201700019A1 publication Critical patent/EA201700019A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

Описаны препараты на основе лекарственной субстанции оритаванцин, имеющие высокую чистоту, наряду с фармацевтическими композициями, содержащими такие препараты на основе лекарственной субстанции оритаванцин, и фармацевтические продукты или лекарственные формы, содержащие такие фармацевтические композиции.
EA201700019A 2014-07-17 2015-07-16 Высокочистый оритаванцин и способ его получения EA201700019A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025737P 2014-07-17 2014-07-17
PCT/US2015/040736 WO2016011245A1 (en) 2014-07-17 2015-07-16 High purity oritavancin and method of producing same

Publications (1)

Publication Number Publication Date
EA201700019A1 true EA201700019A1 (ru) 2017-07-31

Family

ID=55073658

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700019A EA201700019A1 (ru) 2014-07-17 2015-07-16 Высокочистый оритаванцин и способ его получения

Country Status (12)

Country Link
US (3) US9649352B2 (ru)
EP (1) EP3169345A4 (ru)
JP (1) JP6712991B2 (ru)
CN (1) CN107206050A (ru)
AU (1) AU2015289602B2 (ru)
BR (1) BR112017000898A2 (ru)
CA (1) CA2955256C (ru)
EA (1) EA201700019A1 (ru)
HK (1) HK1244447A1 (ru)
MX (1) MX2017000676A (ru)
NZ (1) NZ728401A (ru)
WO (1) WO2016011245A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107793472A (zh) * 2016-09-07 2018-03-13 浙江海正药业股份有限公司 奥利万星二磷酸盐的晶型及其制备方法和用途
CN106928323B (zh) * 2017-03-02 2021-08-20 重庆乾泰生物医药有限公司 一种高纯度奥利万星关键中间体a82846b的制备方法
CN109053864B (zh) * 2018-07-10 2021-08-24 丽珠集团新北江制药股份有限公司 一种制备奥利万星的方法
CN109053865B (zh) * 2018-07-20 2021-04-13 丽珠集团新北江制药股份有限公司 一种羧基保护制备奥利万星的方法
CN109811023B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 A82846b的发酵制备方法
CN109811024B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 发酵制备奥利万星中间体的方法
CN109762860B (zh) * 2019-04-02 2021-10-01 博瑞生物医药泰兴市有限公司 一种碱降解液
CN110824079B (zh) * 2019-11-27 2021-04-13 苏州赛分科技有限公司 特拉万星的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18377A (en) 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US4845194A (en) 1987-02-27 1989-07-04 Eli Lilly And Company Glycopeptide recovery process
IL96603A (en) * 1989-12-13 1998-02-08 Lilly Co Eli Antibacterial glycopeptide derivativesProcess for their preparation and pharmaceutical preparations containing the same
PE40996A1 (es) 1994-01-28 1996-10-14 Lilly Co Eli Derivado de antibiotico de glucopeptido
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
ID18900A (id) * 1996-11-21 1998-05-20 Lilly Co Eli Alkilasi menurun dari gliko peptida anti biotik
US5952466A (en) 1997-11-12 1999-09-14 Eli Lilly And Company Reductive alkylation of glycopeptide antibiotics
US5939382A (en) * 1996-11-21 1999-08-17 Eli Lilly And Company Reducing agent for reductive alkylation of glycopeptide antibiotics
KR100624585B1 (ko) 1998-05-05 2006-09-18 일라이 릴리 앤드 캄파니 카르복스알데히드의 정제
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20050130909A1 (en) 2002-11-18 2005-06-16 Luigi Colombo Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
EP2278989B1 (en) 2008-04-08 2021-05-26 Melinta Therapeutics, Inc. Oritavancin for inhibiting and treating biofilms
WO2010025438A2 (en) * 2008-08-30 2010-03-04 Targanta Therapeutics Corp. Methods of treatment using single doses of oritavancin
PT2424559T (pt) * 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
US8901072B2 (en) 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility

Also Published As

Publication number Publication date
WO2016011245A1 (en) 2016-01-21
CN107206050A (zh) 2017-09-26
US20170157206A1 (en) 2017-06-08
US20190290723A1 (en) 2019-09-26
NZ728401A (en) 2020-08-28
JP6712991B2 (ja) 2020-06-24
US9649352B2 (en) 2017-05-16
MX2017000676A (es) 2018-01-11
EP3169345A1 (en) 2017-05-24
US10864249B2 (en) 2020-12-15
JP2017521443A (ja) 2017-08-03
CA2955256A1 (en) 2016-01-21
US20160015772A1 (en) 2016-01-21
BR112017000898A2 (pt) 2017-11-21
AU2015289602B2 (en) 2020-06-25
AU2015289602A1 (en) 2017-02-09
US10328118B2 (en) 2019-06-25
CA2955256C (en) 2023-02-14
HK1244447A1 (zh) 2018-08-10
EP3169345A4 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
ZA201701719B (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
IL272168A (en) The compositions for increasing the bioavailability of drugs, additives and substances for ingestion
EP3263155A4 (en) Drug solution administering device
EP3157490A4 (en) Affixed groups of pharmaceutical vials including frangible connectors
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
MA42964A (fr) Préparation pharmaceutique anti-vieillissement
IL279594A (en) Pharmaceutical preparations containing low-solubility basic drugs
BR112017020404A2 (pt) medicamento
EP3351286A4 (en) DEVICE FOR THE ADMINISTRATION OF A MEDICAMENT SOLUTION
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EP3326628A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH HIGH-CONCENTRATED TAXAN
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EP3697393A4 (en) PHARMACEUTICAL DOSAGE FORMS
EP3326652A4 (en) Pharmaceutical composition for oral administration comprising high concentration taxane
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.